**Name of Journal:** *World Journal of Gastrointestinal Surgery*

**Manuscript NO:** 73963

**Manuscript Type:** LETTER TO THE EDITOR

**Total mesopancreas excision is the better staging tool of the mesopancreas in pancreatic head carcinoma**

Peparini N. Mesopancreas staging in pancreatic head carcinoma

Nadia Peparini

**Nadia Peparini,** Azienda Sanitaria Locale Roma 6, Distretto 3, Rome 00043, Italy

**Author contributions:** Peparini N conceived, drafted and critically revised the manuscript and gave the final approval.

**Corresponding author: Nadia Peparini, MD, PhD, Doctor,** Azienda Sanitaria Locale Roma 6, Distretto 3, *via* Mario Calò 5, Rome 00043, Italy.

 nadiapeparini@yahoo.it

**Received:** December 9, 2021

**Revised:** April 25, 2022

**Accepted:** June 20, 2022

**Published online:** July 27, 2022

**Abstract**

Preoperative imaging staging based on tumor, node, metastasis classification cannot be effective to avoid R1 resection because only further improvements in imaging technologies will allow the precise assessment of perineural and lymphatic invasion and the occurrence of microscopic tumour deposits in the mesopancreas. However, waiting for further improvements in imaging technologies, total mesopancreas excision remains the only tool able to precisely assess mesopancreatic resection margin status, maximize the guarantee of radicality in cases of negative (R0) mesopancreatic resection margins, and stage the mesopancreas.

**Key Words:** Pancreatic head carcinoma; Mesopancreas; Total mesopancreas excision; Staging; Preoperative imaging; Surgery

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Peparini N. Total mesopancreas excision is the better staging tool of the mesopancreas in pancreatic head carcinoma. *World J Gastrointest Surg* 2022; 14(7): 720-722

**URL**:https://www.wjgnet.com/1948-9366/full/v14/i7/720.htm

**DOI**: https://dx.doi.org/10.4240/wjgs.v14.i7.720

**Core Tip:** To date, among all therapeutic tools, total mesopancreas excision remains the only tool able to precisely assess mesopancreatic resection margin status, maximize the guarantee of radicality in cases of negative (R0) mesopancreatic resection margins, and stage the mesopancreas.

**TO THE EDITOR**

We read with great interest the article by Feng *et al*[1]. The authors note that most R1 resections are related to the insufficient removal of retroperitoneal tissue of the anatomical space recognized as the mesopancreas, and total mesopancreas excision (TMpE) has been proposed to increase the R0 rate of pancreaticoduodenectomies. Consequently, precise preoperative imaging evaluation of pancreatic head carcinoma should include all the nerves, lymphatic vessels, and fatty tissue in the mesopancreas (particularly the structures around the celiac artery and superior mesenteric artery) instead of only traditional masses, vascular invasion, lymph nodes and distant metastasis evaluation. The authors noted that unfortunately, further research is needed to identify the mesopancreas by imaging. To date, neither computed tomography nor magnetic resonance imaging has allowed preoperative evaluation of extrapancreatic perineural invasion, which is important for effective TMpE.

It has been reported that mesopancreatic fat stranding on preoperative multidetector CT scans predicts mesopancreatic cancerous infiltration, which is a significant indicator for incomplete surgical resection and worse overall survival[2].

We think that the following issues should be considered: Imaging evaluation of the mesopancreas facilitates the avoidance of R2 resection risk but not R1 resection risk; Tumour deposits (TDs), *i.e.*, macroscopic or microscopic nests or nodules found in the lymph drainage area of a primary carcinoma without evidence of residual lymph node in the nodule, may occur in pancreatic cancer as well as other digestive carcinomas; TMpE has been conceived to obviate the impossibility of preoperative detection of perineural and lymphatic invasion as well as microscopic TDs in the mesopancreas and to minimize the likelihood of R1 resection or else of “not radical” R0 resection (*i.e.*, unidentified residual TDs after resection with negative margins)[3].

Preoperative imaging staging based on tumor, node, metastasis (TNM) classification cannot be effective to avoid R1 resection because only further improvements in imaging technologies will allow the precise assessment of perineural and lymphatic invasion and the occurrence of microscopic TDs in the mesopancreas. To date, among all therapeutic tools, TMpE remains the only tool able to precisely assess mesopancreatic resection margin status, maximize the guarantee of radicality in cases of negative (R0) mesopancreatic resection margins, and stage the mesopancreas.

Moreover, the occurrence of TDs, the pathologic and prognostic significance of which remains to be determined (T, discontinuous primitive tumour; N, regional nodal metastasis; M, distant metastasis or something else?), underscores the need to overcome the preoperative staging and consequent treatment strategies based on pathological categorization of T, N, and M per the TNM classification system. In the staging and treatment of pancreatic head carcinoma, other pathological pathways and factors beyond T, N, and M that are involved in the modulation of tumour spread should be taken into account.

Precise preoperative imaging evaluation should include all the anatomical structures within the mesopancreas. However, waiting for further improvements in imaging technologies, TMpE remains the better staging tool of the mesopancreas.

**REFERENCES**

1 **Feng P**, Cheng B, Wang ZD, Liu JG, Fan W, Liu H, Qi CY, Pan JJ. Application and progress of medical imaging in total mesopancreas excision for pancreatic head carcinoma. *World J Gastrointest Surg* 2021; **13**: 1315-1326 [PMID: 34950422 DOI: 10.4240/wjgs.v13.i11.1315]

2 **Safi SA**, Haeberle L, Heuveldop S, Kroepil P, Fung S, Rehders A, Keitel V, Luedde T, Fuerst G, Esposito I, Ziayee F, Antoch G, Knoefel WT, Fluegen G. Pre-Operative MDCT Staging Predicts Mesopancreatic Fat Infiltration-A Novel Marker for Neoadjuvant Treatment? *Cancers (Basel)* 2021; **13** [PMID: 34503170 DOI: 10.3390/cancers13174361]

3 **Peparini N**. Paraaortic dissection in "total mesopancreas excision" and "mesopancreas-first resection" pancreaticoduodenectomies for pancreatic cancer: Useless, optional, or necessary?A systematic review. *Surg Oncol* 2021; **38**: 101639 [PMID: 34375818 DOI: 10.1016/j.suronc.2021.101639]

**Footnotes**

**Conflict-of-interest statement:** No conflict of interest exists.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** December 9, 2021

**First decision:** April 19, 2022

**Article in press:** June 20, 2022

**Specialty type:** Surgery

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kawabata Y, Japan; Li L, China; Zhao CF, China **S-Editor:** Zhang H **L-Editor:** A **P-Editor:** Zhang H



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**